

What is claimed is:

Sub E2
1. A lactose-free pharmaceutical composition which comprises an optically pure enantiomer of fluoxetine, 5 or a pharmaceutically acceptable salt thereof, and at least one non-lactose pharmaceutically acceptable excipient.

2. A solid pharmaceutical composition which comprises an optically pure enantiomer of fluoxetine, or a 10 pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein said excipient is not lactose.

3. The composition of claim 1, wherein said non- 15 lactose pharmaceutically acceptable excipient is a binder, a filler, or a mixture thereof.

4. The composition of claim 2, wherein said pharmaceutically acceptable excipient is a binder, a filler, 20 or a mixture thereof.

5. The composition of claim 3 or 4 wherein said binder is a starch.

25 6. The composition of claim 3 or 4 wherein said binder is a cellulose.

Sub B
A1
30 7. The composition of claim 5 wherein said starch is selected from the group consisting of corn starch, potato starch, pre-gelatinized starch and a mixture thereof.

Sub E2
35 8. The composition of claim 6 wherein said cellulose is selected from the group consisting of ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose and a mixture thereof.

Sub E2/ 9. The composition of claim 3 or 4, which further comprises a lubricant, disintegrant, or mixtures thereof.

10. The composition of claim 1 or 2, wherein said 5 enantiomer of fluoxetine is (R)-fluoxetine.

11. The composition of claim 1 or 2, wherein said enantiomer of fluoxetine is (S)-fluoxetine.

Sub E2/ 10 12. The composition of claim 1 or 2, wherein said pharmaceutical composition is substantially free of all mono- or di-saccharides.

15 13. A chemically stable compressed tablet free of lactose which comprises racemic fluoxetine, an optically pure enantiomer of fluoxetine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

Sub E2/ 20 14. A chemically stable compressed tablet free of lactose which comprises about 1% to about 50% by weight of racemic fluoxetine, an optically pure enantiomer or a pharmaceutically acceptable salt thereof, and about 99% to about 50% by weight of at least one pharmaceutically 25 acceptable excipient.

Sub E2/ 15. The compressed tablet of claims 13 or 14 wherein said tablet does not contain a disintegrant.

Sub E2/ 30 16. The compressed tablet of claim 13 or 14 wherein said tablet does not dissolve in less than three 35 minutes when subjected to the DISSOLUTION TEST.

Sub E2/ 17. The composition of claim 13 or 14, wherein 35 said fluoxetine is present in an amount from about 1 mg to about 200 mg.

18. The composition of claim 17, wherein said fluoxetine is present in an amount of about 2 mg to about 100 mg.

5 19. The composition of claim 13 or 14, wherein said fluoxetine enantiomer is optically pure (R)-fluoxetine.

20. The composition of claim 13 or 14, wherein said fluoxetine enantiomer is optically pure (S)-fluoxetine.
10

21. A solid compressed tablet consisting essentially of racemic fluoxetine, an optically pure enantiomer or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose and pre-gelatinized starch.
SUB A3
15

22. The solid pharmaceutical composition of claim 13 or 14, wherein said compressed tablet is sterile, anhydrous and non-hygroscopic.
Sub (3)
20

23. An anhydrous solid pharmaceutical composition which comprises racemic fluoxetine, an optically pure enantiomer of racemic fluoxetine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
sub 1
25

24. The composition of claim 23 wherein said composition does not contain lactose.
sub 2
sub 22

25. The composition of claim 23 or 24 wherein said composition is a compressed tablet.
30

26. The composition of claim 23 or 24 wherein said fluoxetine enantiomer is optically pure (R)-fluoxetine.

27. The composition of claim 23 or 24 wherein said fluoxetine enantiomer is optically pure (S)-fluoxetine.
35

Sub
Ct
28. The composition of claim 23 or 24 wherein said composition is non-hygroscopic.

29. The composition of claim 1, 13, 14, 21, 23, or 24 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

Sub
R4
30. A stable solid pharmaceutical unit dosage form which comprises racemic fluoxetine, an optically pure enantiomer of racemic fluoxetine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients wherein said dosage form is not a capsule or gel cap.

15 31. The unit dosage form of claim 30 wherein said fluoxetine enantiomer is optically pure (R)-fluoxetine.

32. The unit dosage form of claim 30 wherein said fluoxetine enantiomer is optically pure (S)-fluoxetine.

20 33. A solid compressed tablet substantially free of lactose which comprises an optically pure enantiomer of fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient which is not lactose.

34. A disintegrating tablet substantially free of lactose which comprises an optically pure enantiomer of fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient which is not lactose.

35. A method of treating depression in a mammal which comprises the oral administration of a therapeutically effective amount of a composition of claims 1, 2, 13, 14, 21, 23, 24, 30, 33 or 34 to said mammal.